TISIDB

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cell cortex. Cytoplasm, cytoskeleton.
Domain	PF00307 Calponin homology (CH) domain PF00630 Filamin/ABP280 repeat
Function	Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking (By similarity). Involved in ciliogenesis. Plays a role in cell-cell contacts and adherens junctions during the development of blood vessels, heart and brain organs. Plays a role in platelets morphology through interaction with SYK that regulates ITAM- and ITAM-like-containing receptor signaling, resulting in by platelet cytoskeleton organization maintenance (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0002011 morphogenesis of an epithelial sheet GO:0002576 platelet degranulation GO:0006356 regulation of transcription from RNA polymerase I promoter GO:0006360 transcription from RNA polymerase I promoter GO:0006606 protein import into nucleus GO:0006887 exocytosis GO:0006913 nucleocytoplasmic transport GO:0007015 actin filament organization GO:0007051 spindle organization GO:0007067 mitotic nuclear division GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007195 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007212 dopamine receptor signaling pathway GO:0007229 integrin-mediated signaling pathway GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007596 blood coagulation GO:0007599 hemostasis GO:0009299 mRNA transcription GO:0009894 regulation of catabolic process GO:0009895 negative regulation of catabolic process GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0010927 cellular component assembly involved in morphogenesis GO:0016479 negative regulation of transcription from RNA polymerase I promoter GO:0017038 protein import GO:0022604 regulation of cell morphogenesis GO:0030031 cell projection assembly GO:0030168 platelet activation GO:0031532 actin cytoskeleton reorganization GO:0031589 cell-substrate adhesion GO:0031647 regulation of protein stability GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032507 maintenance of protein location in cell GO:0033157 regulation of intracellular protein transport GO:0034109 homotypic cell-cell adhesion GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0034394 protein localization to cell surface GO:0034446 substrate adhesion-dependent cell spreading GO:0034504 protein localization to nucleus GO:0042176 regulation of protein catabolic process GO:0042177 negative regulation of protein catabolic process GO:0042306 regulation of protein import into nucleus GO:0042307 positive regulation of protein import into nucleus GO:0042384 cilium assembly GO:0042789 mRNA transcription from RNA polymerase II promoter GO:0042990 regulation of transcription factor import into nucleus GO:0042991 transcription factor import into nucleus GO:0042993 positive regulation of transcription factor import into nucleus GO:0043113 receptor clustering GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0044319 wound healing, spreading of cells GO:0044744 protein targeting to nucleus GO:0044782 cilium organization GO:0045055 regulated exocytosis GO:0045185 maintenance of protein location GO:0045785 positive regulation of cell adhesion GO:0046822 regulation of nucleocytoplasmic transport GO:0046824 positive regulation of nucleocytoplasmic transport GO:0050817 coagulation GO:0050821 protein stabilization GO:0050878 regulation of body fluid levels GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051220 cytoplasmic sequestering of protein GO:0051222 positive regulation of protein transport GO:0051225 spindle assembly GO:0051235 maintenance of location GO:0051651 maintenance of location in cell GO:0051668 localization within membrane GO:0051764 actin crosslink formation GO:0060271 cilium morphogenesis GO:0070527 platelet aggregation GO:0071526 semaphorin-plexin signaling pathway GO:0072657 protein localization to membrane GO:0090307 mitotic spindle assembly GO:0090316 positive regulation of intracellular protein transport GO:0090504 epiboly GO:0090505 epiboly involved in wound healing GO:1900024 regulation of substrate adhesion-dependent cell spreading GO:1900026 positive regulation of substrate adhesion-dependent cell spreading GO:1900180 regulation of protein localization to nucleus GO:1900182 positive regulation of protein localization to nucleus GO:1902593 single-organism nuclear import GO:1902850 microtubule cytoskeleton organization involved in mitosis GO:1903533 regulation of protein targeting GO:1903829 positive regulation of cellular protein localization GO:1904589 regulation of protein import GO:1904591 positive regulation of protein import GO:1904951 positive regulation of establishment of protein localization GO:2001044 regulation of integrin-mediated signaling pathway GO:2001046 positive regulation of integrin-mediated signaling pathway
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0001948 glycoprotein binding GO:0003779 actin binding GO:0008134 transcription factor binding GO:0017016 Ras GTPase binding GO:0017048 Rho GTPase binding GO:0017160 Ral GTPase binding GO:0031267 small GTPase binding GO:0031628 opioid receptor binding GO:0031852 mu-type opioid receptor binding GO:0034987 immunoglobulin receptor binding GO:0034988 Fc-gamma receptor I complex binding GO:0045296 cadherin binding GO:0046332 SMAD binding GO:0048365 Rac GTPase binding GO:0050839 cell adhesion molecule binding GO:0051015 actin filament binding GO:0051020 GTPase binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005884 actin filament GO:0005913 cell-cell adherens junction GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0030055 cell-substrate junction GO:0030425 dendrite GO:0030863 cortical cytoskeleton GO:0031523 Myb complex GO:0031941 filamentous actin GO:0043025 neuronal cell body GO:0043198 dendritic shaft GO:0044297 cell body GO:0044448 cell cortex part GO:0097440 apical dendrite GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04510 Focal adhesion
Reactome	R-HSA-446728: Cell junction organization R-HSA-1500931: Cell-Cell communication R-HSA-446353: Cell-extracellular matrix interactions R-HSA-430116: GP1b-IX-V activation signalling R-HSA-109582: Hemostasis R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-195258: RHO GTPase Effectors R-HSA-5627123: RHO GTPases activate PAKs R-HSA-76005: Response to elevated platelet cytosolic Ca2+ R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04510 Focal adhesion

Reactome

R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-446353: Cell-extracellular matrix interactions
R-HSA-430116: GP1b-IX-V activation signalling
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FLNA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FLNA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FLNA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.006	0.985
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.318	0.924
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.218	0.927
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.546	0.429
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.47	0.911
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.643	0.905
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.227	0.698
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.053	0.983
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.43	0.876
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.181	0.684
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.562	0.722
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.329	0.0232

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FLNA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	1.4	13.4	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	1.7	13.1	0.032
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FLNA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FLNA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FLNA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FLNA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FLNA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FLNA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FLNA
Name	filamin A, alpha
Aliases	FLN1; FLN; OPD2; OPD1; filamin A, alpha (actin binding protein 280); ABPX; CVD1; FLN-A; NHBP; OPD; XLVD; XMV ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FLNA collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FLNA.

ID	Name	Drug Type	Targets	#Targets
DB11638	Artenimol	Small Molecule	ACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......	79

Browse FLNA